Acropetal Genetics Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -23.33%
- Profit Growth 91.34%
- Ebitda 45.51%
- Net Worth 65.46%
- Total Assets -8.17%
About Acropetal Genetics
Acropetal Genetics Private Limited (AGPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 11 July 2014 and has a history of Ten years and seven months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Sarang Dhande, Rajesh Patel, and Dipak Bagul serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U01403GJ2014PTC080096
- Company No.
080096
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jul 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Acropetal Genetics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Patel  | Managing Director | 11-Jul-2014 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Dipak Bagul | Director | 11-Jul-2014 | Current |
| Sarang Dhande | Director | 11-Jul-2014 | Current |
Financial Performance of Acropetal Genetics.
Acropetal Genetics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 23.33% decrease. The company also saw a substantial improvement in profitability, with a 91.34% increase in profit. The company's net worth Soared by an impressive increase of 65.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Acropetal Genetics?
In 2023, Acropetal Genetics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Agreesha Wealth Finserv LlpSarang Dhande is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Acropetal Genetics?
Unlock and access historical data on people associated with Acropetal Genetics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Acropetal Genetics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Acropetal Genetics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.